Sandoz Group AG (SDZNY)

OTCMKTS · Delayed Price · Currency is USD
44.02
+0.14 (0.32%)
Aug 30, 2024, 4:00 PM EDT
64.75%
Market Cap 18.88B
Revenue (ttm) 10.11B
Net Income (ttm) -8.00M
Shares Out n/a
EPS (ttm) -0.02
PE Ratio n/a
Forward PE n/a
Dividend 0.38 (0.87%)
Ex-Dividend Date May 3, 2024
Volume 7,950
Open 44.20
Previous Close 43.88
Day's Range 43.86 - 44.36
52-Week Range 25.71 - 44.98
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Mar 5, 2025

About Sandoz Group AG

Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland. [Read more]

Sector Healthcare
Founded 1886
Employees 22,633
Stock Exchange OTCMKTS
Ticker Symbol SDZNY
Full Company Profile

Financial Performance

In 2023, SDZNY's revenue was $9.98 billion, an increase of 7.23% compared to the previous year's $9.31 billion. Earnings were $77.00 million, a decrease of -90.92%.

Financial Statements

News

Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar position

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Enzeevu™ (aflibercept-abzv) approved to treat neovascular age-related macular degeneration Further enhances leading US ophthalm...

19 days ago - GlobeNewsWire

Sandoz Group AG (SDZNY) (Q2 2024) Earnings Call Transcript Highlights: Strong Biosimilars ...

Sandoz Group AG (SDZNY) (Q2 2024) Earnings Call Transcript Highlights: Strong Biosimilars Growth and Raised Sales Guidance

22 days ago - GuruFocus

Half Year 2024 Sandoz Group AG Earnings Call Transcript

Half Year 2024 Sandoz Group AG Earnings Call Transcript

22 days ago - GuruFocus

Won't see major development in weight loss indication drugs in EU or U.S. until 2030, Sandoz CEO says

Richard Saynor, CEO of Sandoz, discusses the firm's half-year results and shares his outlook for innovation in the weight loss drug market.

23 days ago - CNBC

Generic weight-loss drugs? They’re coming — eventually, executive says

Sandoz, the generics drugmaker spun off from Novartis, is going to get into making cheap versions of the wildly popular GLP-1 class of drugs to treat diabetes and weight loss. But it may take a while.

23 days ago - MarketWatch

Sandoz reports second-quarter sales and half-year 2024 results

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong double-digit growth in biosimilars of 29% from existing portfolio and recent launches Second-quarter net s...

23 days ago - GlobeNewsWire

Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases Launch across Europe, ...

5 weeks ago - GlobeNewsWire

FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US Pyzchiva® (ustekinumab-ttwe) is appr...

2 months ago - GlobeNewsWire

Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Wyost® (denosumab) and Jubbonti® (denosumab) approved by EC for all indications of denosumab reference medicines ...

3 months ago - GlobeNewsWire

Sandoz reports first quarter 2024 sales

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong first quarter performance, with net sales [1] of USD 2.5 billion, up 6% in constant currencies (up 5% in U...

4 months ago - GlobeNewsWire

Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG

All proposals of Board of Directors approved Gilbert Ghostine re-elected as Chairman of Board of Directors; all other Board members standing for election confirmed Mathai Mammen, Graeme Pitkethly and ...

4 months ago - GlobeNewsWire

Sandoz reaches agreement with Amgen over patent dispute

Swiss generic and biosimilar manufacturer Sandoz said on Tuesday it had reached an agreement with U.S. drugmaker Amgen resolving all patent litigation related to its U.S. denosumab biosimilars.

4 months ago - Reuters

Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars Agreement clears pa...

4 months ago - GlobeNewsWire

Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offering

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Pyzchiva® approved as one of first ustekinumab biosimilars in Europe EC approval based on robust development program confirming...

4 months ago - GlobeNewsWire

Sandoz opens new antibiotic production facility in Austria, to significantly increase capacity for life-saving medicines

MEDIA RELEASE EUR 50m investment in Kundl plant extension emphasizes commitment to serve more patients with critical antibiotics, produced entirely in Europe Additional manufacturing area of 3,000m2 m...

5 months ago - GlobeNewsWire

Sandoz reports fourth quarter 2023 sales and full-year 2023 results

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong fourth quarter performance, with net sales1 of USD 2.5 billion, up 10% in constant currencies (up 11% in U...

6 months ago - GlobeNewsWire

Sandoz receives FDA approval for first and only denosumab biosimilars

MEDIA RELEASE Wyost® (denosumab-bddz) and Jubbonti® (denosumab-bddz) interchangeable with and approved by FDA for all indications of reference medicines Xgeva ®* (denosumab) and Prolia®* (denosumab) F...

6 months ago - GlobeNewsWire